Akhilesh Swaminathan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akhilesh Swaminathan has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Richard Blair Gearry
Department of Medicine University of Otago Christchurch Christchurch New Zealand
8 shared publications Grace M Borichevsky
Mātai Hāora—Centre for Redox Biology and Medicine, Department of Pathology and Biomedical Science, University of Otago Christchurch , Christchurch
7 shared publications- Andrew Stewart Day
Paediatrics Department Christchurch Hospital Christchurch New Zealand
6 shared publications Richard B Gearry
Department of Medicine, University of Otago , Christchurch
5 shared publicationsChris M Frampton
Department of Medicine, University of Otago Christchurch , Christchurch
4 shared publicationsAndrew S Day
Department of Paediatrics, University of Otago , Christchurch
3 shared publications
Latest Publications
- 30 March 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (11) , 1565-1566
Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease
- 30 March 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (11) , 1565-1566
Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease
- Open Access
Factors Associated With Loss of Fecal Biomarker Accuracy During Routine Assessment of Inflammatory Bowel Disease
Background: Fecal calprotectin (fCal) and fecal myeloperoxidase (fMPO) have been proposed as biomarkers for monitoring inflammatory bowel disease (IBD); however, their reliability is not fully established. This study investigated clinical variables associated with the loss of accuracy of fecal biomarkers. Methods: Post hoc analyses were performed on previously reported data (New indicators of disease activity in IBD (NIDA‐IBD) cohort), which examined fecal biomarkers in individuals with IBD undergoing colonoscopy. Positive and negative results were recorded using previously identified thresholds (fCal, 150 μg/g; fMPO, 8 μg/g). Univariable logistic regression analyses were used to identify clinical variables (patient demographics, disease location and duration, symptoms and medication use) associated with false‐positive and false‐negative results. Subgroup analyses (Mann–Whitney U test) were performed to establish if the presence of colonic pseudopolyps was associated with fCal and fMPO concentrations in those with endoscopically inactive disease. Results: One hundred and seventy individuals from the NIDA‐IBD cohort were included for analyses (CD, n = 98; female, n = 90; median disease duration 13 years). No clinical variables investigated were associated with a false positive or false negative result. Pseudopolyp presence was not associated with fCal or fMPO concentrations in those with endoscopically inactive disease. Positive and negative predictive values were higher using fecal biomarkers in combination with symptom scores than using symptom scores alone in predicting/excluding endoscopic activity. Conclusions: No clinical variables were found to be associated with loss of biomarker accuracy, including fecal myeloperoxidase at widely used thresholds. Fecal biomarkers improved prediction of disease activity.
Open AccessFactors Associated With Loss of Fecal Biomarker Accuracy During Routine Assessment of Inflammatory Bowel Disease
Background: Fecal calprotectin (fCal) and fecal myeloperoxidase (fMPO) have been proposed as biomarkers for monitoring inflammatory bowel disease (IBD); however, their reliability is not fully established. This study investigated clinical variables associated with the loss of accuracy of fecal biomarkers. Methods: Post hoc analyses were performed on previously reported data (New indicators of disease activity in IBD (NIDA‐IBD) cohort), which examined fecal biomarkers in individuals with IBD undergoing colonoscopy. Positive and negative results were recorded using previously identified thresholds (fCal, 150 μg/g; fMPO, 8 μg/g). Univariable logistic regression analyses were used to identify clinical variables (patient demographics, disease location and duration, symptoms and medication use) associated with false‐positive and false‐negative results. Subgroup analyses (Mann–Whitney U test) were performed to establish if the presence of colonic pseudopolyps was associated with fCal and fMPO concentrations in those with endoscopically inactive disease. Results: One hundred and seventy individuals from the NIDA‐IBD cohort were included for analyses (CD, n = 98; female, n = 90; median disease duration 13 years). No clinical variables investigated were associated with a false positive or false negative result. Pseudopolyp presence was not associated with fCal or fMPO concentrations in those with endoscopically inactive disease. Positive and negative predictive values were higher using fecal biomarkers in combination with symptom scores than using symptom scores alone in predicting/excluding endoscopic activity. Conclusions: No clinical variables were found to be associated with loss of biomarker accuracy, including fecal myeloperoxidase at widely used thresholds. Fecal biomarkers improved prediction of disease activity.
- 21 August 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (11) , 3242-3243
Author’s Response to Comment on “Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease”
- 21 August 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (11) , 3242-3243
Author’s Response to Comment on “Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease”
- Open Access
- 24 May 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (8) , 2254-2268
Myeloperoxidase Enzyme Activity in Feces Reflects Endoscopic Severity in Inflammatory Bowel Disease
Background: Concentrations of the neutrophil protein myeloperoxidase are elevated in the feces of individuals with endoscopically active inflammatory bowel disease (IBD). Its enzyme activity could give an immediate readout of endoscopic inflammation. We investigated whether fecal myeloperoxidase activity (fMPOa) is associated with IBD endoscopic inflammation. We also investigated whether myeloperoxidase promotes oxidative stress in IBD. Methods: Myeloperoxidase enzyme activity was measured using an enzyme-linked immunosorbent assay (ELISA fMPOa), a novel CM-sepharose extraction assay (CM-S fMPOa), or by quantifying urinary glutathione sulfonamide (GSA) by tandem mass spectrometry. GSA is a specific biomarker of myeloperoxidase activity. IBD activity was assessed using the ulcerative colitis endoscopic index of severity or the simple endoscopic score for Crohn’s disease (SES-CD). Spearman’s correlation and receiver operating characteristic curves evaluated biomarker utility. Results: IBD patients (n = 172) were recruited prospectively (ulcerative colitis, n = 72; Crohn’s disease, n = 100). fMPO was mostly active. Its enzyme activity, measured either as ELISA fMPOa or CM-S fMPOa, correlated with endoscopic inflammation in both ulcerative colitis and Crohn’s disease. Urinary GSA is also correlated with endoscopic disease inflammation. Correlations of urinary GSA with disease measures and other biomarkers were stronger in ulcerative colitis than in Crohn’s disease. Conclusions: Myeloperoxidase is active in IBD and its enzyme activity is a reliable marker of IBD endoscopic inflammation. Our results with the CM-S fMPOa assay demonstrate the potential for an immediate and accurate measure of fMPO enzyme activity as a robust, low-cost test for IBD activity. Myeloperoxidase may contribute to tissue damage in IBD.
- 24 May 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (8) , 2254-2268
Open AccessMyeloperoxidase Enzyme Activity in Feces Reflects Endoscopic Severity in Inflammatory Bowel Disease
Background: Concentrations of the neutrophil protein myeloperoxidase are elevated in the feces of individuals with endoscopically active inflammatory bowel disease (IBD). Its enzyme activity could give an immediate readout of endoscopic inflammation. We investigated whether fecal myeloperoxidase activity (fMPOa) is associated with IBD endoscopic inflammation. We also investigated whether myeloperoxidase promotes oxidative stress in IBD. Methods: Myeloperoxidase enzyme activity was measured using an enzyme-linked immunosorbent assay (ELISA fMPOa), a novel CM-sepharose extraction assay (CM-S fMPOa), or by quantifying urinary glutathione sulfonamide (GSA) by tandem mass spectrometry. GSA is a specific biomarker of myeloperoxidase activity. IBD activity was assessed using the ulcerative colitis endoscopic index of severity or the simple endoscopic score for Crohn’s disease (SES-CD). Spearman’s correlation and receiver operating characteristic curves evaluated biomarker utility. Results: IBD patients (n = 172) were recruited prospectively (ulcerative colitis, n = 72; Crohn’s disease, n = 100). fMPO was mostly active. Its enzyme activity, measured either as ELISA fMPOa or CM-S fMPOa, correlated with endoscopic inflammation in both ulcerative colitis and Crohn’s disease. Urinary GSA is also correlated with endoscopic disease inflammation. Correlations of urinary GSA with disease measures and other biomarkers were stronger in ulcerative colitis than in Crohn’s disease. Conclusions: Myeloperoxidase is active in IBD and its enzyme activity is a reliable marker of IBD endoscopic inflammation. Our results with the CM-S fMPOa assay demonstrate the potential for an immediate and accurate measure of fMPO enzyme activity as a robust, low-cost test for IBD activity. Myeloperoxidase may contribute to tissue damage in IBD.
- Open Access
- 24 May 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (11) , 3003-3010
Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease
Background: Inflammatory bowel disease (IBD) is a relapsing-remitting illness requiring proactive monitoring of gut inflammation. We aimed to determine the correlations of plasma myeloperoxidase (pMPO) and calprotectin (pCal), two neutrophil proteins, with existing measures of disease activity. Methods: Adults with IBD undergoing ileocolonoscopy were recruited prospectively. Baseline assessments included blood tests (pMPO, pCal, and C-reactive protein ([CRP]), symptom questionnaires, and endoscopic indices (simple endoscopic score for CD [SES-CD] and UC endoscopic index of severity [UCEIS]). Active IBD was defined as SES-CD > 2 and UCEIS ≥ 2. Spearman’s rank correlations assessed the associations between blood markers and endoscopic activity. The area under the receiver operating characteristics curves (AUROC) and univariable logistic regression assessed the ability of blood markers (at optimal thresholds) to identify active disease. Results: In total, 170 participants were included (female, n = 92; Crohn’s disease [CD], n = 99; median age 46 years, IQR 35-58). Plasma biomarkers more accurately identified active IBD in individuals with UC (AUROCpMPO = 0.76, P < .001; AUROCpCal = 0.66, P < .05; AUROCCRP = 0.73, P < .001) than in CD (AUROCpMPO = 0.62, P > .05; AUROCpCal = 0.65, P < .01; AUROCCRP = 0.66, P < .01). In all patients with IBD, the addition of pCal (AUROC = 0.73, P < .001) and pMPO (AUROC = 0.73, P < .001) to CRP added benefit compared to CRP (AUROC = 0.70, P < .001) alone. Plasma myeloperoxidase > 13.86 ng/mL (odds ratio [OR] = 10.13, 3.4-30.16) and pCal > 961.72 ng/mL (OR = 3.38, 1.21-9.4) were associated with an increased odds of having endoscopically active UC. Conclusions: Plasma MPO shows promise as a potential blood-based biomarker of IBD activity, especially in UC. The combined use of pMPO and CRP adds diagnostic utility in discriminating between active versus quiescent IBD.
- 24 May 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (11) , 3003-3010
Open AccessPlasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease
Background: Inflammatory bowel disease (IBD) is a relapsing-remitting illness requiring proactive monitoring of gut inflammation. We aimed to determine the correlations of plasma myeloperoxidase (pMPO) and calprotectin (pCal), two neutrophil proteins, with existing measures of disease activity. Methods: Adults with IBD undergoing ileocolonoscopy were recruited prospectively. Baseline assessments included blood tests (pMPO, pCal, and C-reactive protein ([CRP]), symptom questionnaires, and endoscopic indices (simple endoscopic score for CD [SES-CD] and UC endoscopic index of severity [UCEIS]). Active IBD was defined as SES-CD > 2 and UCEIS ≥ 2. Spearman’s rank correlations assessed the associations between blood markers and endoscopic activity. The area under the receiver operating characteristics curves (AUROC) and univariable logistic regression assessed the ability of blood markers (at optimal thresholds) to identify active disease. Results: In total, 170 participants were included (female, n = 92; Crohn’s disease [CD], n = 99; median age 46 years, IQR 35-58). Plasma biomarkers more accurately identified active IBD in individuals with UC (AUROCpMPO = 0.76, P < .001; AUROCpCal = 0.66, P < .05; AUROCCRP = 0.73, P < .001) than in CD (AUROCpMPO = 0.62, P > .05; AUROCpCal = 0.65, P < .01; AUROCCRP = 0.66, P < .01). In all patients with IBD, the addition of pCal (AUROC = 0.73, P < .001) and pMPO (AUROC = 0.73, P < .001) to CRP added benefit compared to CRP (AUROC = 0.70, P < .001) alone. Plasma myeloperoxidase > 13.86 ng/mL (odds ratio [OR] = 10.13, 3.4-30.16) and pCal > 961.72 ng/mL (OR = 3.38, 1.21-9.4) were associated with an increased odds of having endoscopically active UC. Conclusions: Plasma MPO shows promise as a potential blood-based biomarker of IBD activity, especially in UC. The combined use of pMPO and CRP adds diagnostic utility in discriminating between active versus quiescent IBD.
- 1 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (9) , 1577-1578
Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
- 1 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (9) , 1577-1578
Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
- 10 January 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (5) , 895-896
Editorial: Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
- 10 January 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (5) , 895-896
Editorial: Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
- Open Access
- 11 November 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (3) , 800-811
Fecal Myeloperoxidase Levels Reflect Disease Activity in Children With Crohn’s Disease
Background: Crohn’s disease (CD) is a major form of inflammatory bowel disease (IBD) which has relapsing and remitting symptoms. Better ways to detect and monitor active disease are required for early diagnosis and optimal outcomes. We assessed fecal myeloperoxidase (fMPO), a neutrophil-derived enzyme that produces hypochlorous acid, as a marker of disease activity in children with CD. Methods: This observational study assessed myeloperoxidase (MPO) levels in fecal samples from children aged <17 years with CD (51 with active or 42 inactive disease) measured by enzyme-linked immunosorbent assay (ELISA) and compared to controls (35 healthy siblings and 15 unrelated well children). Results were correlated with fecal calprotectin, serum C-reactive protein, urinary glutathione sulfonamide (a biomarker of hypochlorous acid), and disease activity scores. Differences between groups were assessed by analysis of variance. Receiver-operating-characteristic curves were used to assess how biomarkers predicted disease and disease activity. Results: Fecal myeloperoxidase activity and fMPO protein correlated with fecal calprotectin (r = 0.78, P < .0001, and r = 0.81, P < .0001, respectively). Fecal myeloperoxidase activity and protein levels were significantly higher (P ≤ .0001) in individuals with active disease compared to healthy sibling controls, unrelated well children, and those with inactive disease. A 9.7 µg/g fMPO protein cutoff distinguished inactive from active disease (sensitivity = 75%, specificity = 76%). Urinary GSA was elevated in children with active disease (P < .0001) and correlated with fMPO protein (r = 0.43, P = .0002) in a subset of 72 children with IBD and controls. Conclusions: Fecal myeloperoxidase may be superior to fCal at reflecting disease severity in children with CD and produces the damaging oxidant hypochlorous acid during active inflammation.
- 11 November 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (3) , 800-811
Open AccessFecal Myeloperoxidase Levels Reflect Disease Activity in Children With Crohn’s Disease
Background: Crohn’s disease (CD) is a major form of inflammatory bowel disease (IBD) which has relapsing and remitting symptoms. Better ways to detect and monitor active disease are required for early diagnosis and optimal outcomes. We assessed fecal myeloperoxidase (fMPO), a neutrophil-derived enzyme that produces hypochlorous acid, as a marker of disease activity in children with CD. Methods: This observational study assessed myeloperoxidase (MPO) levels in fecal samples from children aged <17 years with CD (51 with active or 42 inactive disease) measured by enzyme-linked immunosorbent assay (ELISA) and compared to controls (35 healthy siblings and 15 unrelated well children). Results were correlated with fecal calprotectin, serum C-reactive protein, urinary glutathione sulfonamide (a biomarker of hypochlorous acid), and disease activity scores. Differences between groups were assessed by analysis of variance. Receiver-operating-characteristic curves were used to assess how biomarkers predicted disease and disease activity. Results: Fecal myeloperoxidase activity and fMPO protein correlated with fecal calprotectin (r = 0.78, P < .0001, and r = 0.81, P < .0001, respectively). Fecal myeloperoxidase activity and protein levels were significantly higher (P ≤ .0001) in individuals with active disease compared to healthy sibling controls, unrelated well children, and those with inactive disease. A 9.7 µg/g fMPO protein cutoff distinguished inactive from active disease (sensitivity = 75%, specificity = 76%). Urinary GSA was elevated in children with active disease (P < .0001) and correlated with fMPO protein (r = 0.43, P = .0002) in a subset of 72 children with IBD and controls. Conclusions: Fecal myeloperoxidase may be superior to fCal at reflecting disease severity in children with CD and produces the damaging oxidant hypochlorous acid during active inflammation.